Aethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued on Friday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright cut their price objective on Aethlon Medical from $23.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, March 4th.

Aethlon Medical Stock Performance

NASDAQ AEMD opened at $1.51 on Friday. Aethlon Medical has a twelve month low of $1.40 and a twelve month high of $7.20. The stock has a market capitalization of $3.96 million, a PE ratio of -0.30 and a beta of 1.88. The stock has a 50-day simple moving average of $1.70 and a 200 day simple moving average of $1.79.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings data on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.14). As a group, equities research analysts forecast that Aethlon Medical will post -4.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Aethlon Medical

Several large investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP raised its holdings in Aethlon Medical by 219.3% in the 1st quarter. Two Sigma Investments LP now owns 127,341 shares of the medical equipment provider’s stock valued at $49,000 after acquiring an additional 87,458 shares in the last quarter. Jane Street Group LLC raised its holdings in Aethlon Medical by 895.7% in the 4th quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 126,160 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Aethlon Medical by 61.4% in the 4th quarter. Renaissance Technologies LLC now owns 100,600 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 38,264 shares in the last quarter. HRT Financial LP acquired a new position in Aethlon Medical in the 4th quarter valued at approximately $28,000. Finally, Vanguard Group Inc. raised its holdings in Aethlon Medical by 112.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock valued at $613,000 after acquiring an additional 558,596 shares in the last quarter. Institutional investors and hedge funds own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.